JP2024502178A5 - - Google Patents

Info

Publication number
JP2024502178A5
JP2024502178A5 JP2023541702A JP2023541702A JP2024502178A5 JP 2024502178 A5 JP2024502178 A5 JP 2024502178A5 JP 2023541702 A JP2023541702 A JP 2023541702A JP 2023541702 A JP2023541702 A JP 2023541702A JP 2024502178 A5 JP2024502178 A5 JP 2024502178A5
Authority
JP
Japan
Application number
JP2023541702A
Other languages
Japanese (ja)
Other versions
JPWO2022150911A5 (https=
JP2024502178A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2022/050038 external-priority patent/WO2022150911A1/en
Publication of JP2024502178A publication Critical patent/JP2024502178A/ja
Publication of JP2024502178A5 publication Critical patent/JP2024502178A5/ja
Publication of JPWO2022150911A5 publication Critical patent/JPWO2022150911A5/ja
Pending legal-status Critical Current

Links

JP2023541702A 2021-01-13 2022-01-12 Sgk-1を阻害するためのピラゾロ[3,4-d]ピリミジン-6-イル-スルホンアミド誘導体 Pending JP2024502178A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163136782P 2021-01-13 2021-01-13
US63/136,782 2021-01-13
US202163262040P 2021-10-04 2021-10-04
US63/262,040 2021-10-04
PCT/CA2022/050038 WO2022150911A1 (en) 2021-01-13 2022-01-12 Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1

Publications (3)

Publication Number Publication Date
JP2024502178A JP2024502178A (ja) 2024-01-17
JP2024502178A5 true JP2024502178A5 (https=) 2025-01-17
JPWO2022150911A5 JPWO2022150911A5 (https=) 2025-01-17

Family

ID=82446316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541702A Pending JP2024502178A (ja) 2021-01-13 2022-01-12 Sgk-1を阻害するためのピラゾロ[3,4-d]ピリミジン-6-イル-スルホンアミド誘導体

Country Status (8)

Country Link
US (1) US20240309005A1 (https=)
EP (1) EP4277905A4 (https=)
JP (1) JP2024502178A (https=)
KR (1) KR20230136622A (https=)
CN (1) CN121517419A (https=)
AU (1) AU2022208639A1 (https=)
MX (1) MX2023008219A (https=)
WO (1) WO2022150911A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250085708A (ko) * 2022-07-12 2025-06-12 쓰리브 테라퓨틱스 인크. N-[4-[4-[[2-(디메틸아미노)에틸]아미노]-3-메틸-1H-피라졸로[3,4-d]피리미딘-6-일)-2-플루오로페닐]-2,5-디플루오로벤젠설폰아미드의염 및 이의 결정 형태
WO2024015055A1 (en) * 2022-07-13 2024-01-18 Thryv Therapeutics Inc. Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 and treatment of cancer
KR102912267B1 (ko) * 2023-04-20 2026-01-15 한국화학연구원 신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
CN121909195A (zh) * 2023-09-27 2026-04-21 百时美施贵宝公司 作为sgk1抑制剂的哌啶取代的吡唑并嘧啶衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5827849B2 (ja) * 2011-09-20 2015-12-02 サノフイ N−[4−(1H−ピラゾロ[3,4−b]ピラジン−6−イル)−フェニル]−スルホンアミド及び薬剤としてのその使用
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途
PT3049085T (pt) * 2013-09-26 2021-10-01 Beth Israel Deaconess Medical Ct Inc Inibidores de sgk1 no tratamento da síndrome do qt longo
US11236083B2 (en) * 2016-12-07 2022-02-01 Orimos Therapeutics Co., Ltd. Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof

Similar Documents

Publication Publication Date Title
JP2024502178A5 (https=)
CL2025003148A1 (es) Proceso y aparato para preparar trióxido de azufre a partir de dióxido de azufre
CL2025003924A1 (es) Sistemas y métodos para explosión comercial.
BR102023014872A2 (https=)
BR102023001877A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BY13164U (https=)
BY13159U (https=)
CN307045712S (https=)
CN307045099S (https=)
CN307044234S (https=)
CN307044224S (https=)
BY23963C1 (https=)
BY13175U (https=)
BY13174U (https=)
BY13172U (https=)
BY13170U (https=)
BY13169U (https=)
BY13168U (https=)
BY13167U (https=)
BY13166U (https=)
BY13165U (https=)
CN307048273S (https=)